(City)

(Last)

(State)

(First)

1. Name and Address of Reporting Person*

TRV GP III, LLC

(Zip)

(Middle)

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

bject	STATEMENT OF CHA

OMB APPROVAL 3235-0287 NGES IN BENEFICIAL OWNERSHIP Estimated average burden

0.5

7. Nature of Indirect Beneficial Ownership (Instr. 4)

11. Nature of Indirect Beneficial Ownership (Instr. 4)

to Section 16. Form 4 or Form 5 obligations may continue. See					pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 OMB Number: 3235-0287 Estimated average burden hours per response: 0.5																
						2. Issuer Name and Ticker or Trading Symbol Voyager Therapeutics, Inc. [VYGR]											all appl	licable) tor	X 10% C		wner
1	IRD ROCK	rst) (I VENTURES, L AVE, SUITE 140					of Ea		Trans	action (Month	n/Day/Year)					below	r (give title	; 	below)	(specify
(Street)	N M	A 0)2215		4. If	Ame	endm	ent, [Date o	of Origin	al File	ed (Month/Da	y/Year	.)	Line		Form	filed by O filed by M	ne Re	ing (Check <i>F</i> eporting Pers nan One Rep	son
(City)	(Si	tate) (2	Zip)																		
		Table	I - No	n-Deriva	ative	Sec	curi	ties	Acc	uired	, Dis	posed of	, or I	3en	eficia	lly	Owne	ed			
1. Title of Security (Instr. 3)				2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)			s Acquired (A) of (D) (Instr. 3, 4			4 and S		5. Amount of Securities Beneficially Owned Following Reported		Ownership rm: Direct or Indirect (Instr. 4)	7. Nature of Indirec Beneficia Ownershi (Instr. 4)		
										Code	v	Amount	(A) (D)	or	Price			ction(s)			, ,,
Common	Stock			01/24/2	2023					S		100,000	I		\$9.27	(1)	5,1′	73,933		D ⁽²⁾	
Common	Stock			01/25/2	2023					S		50,000	I		\$9.22	(3)	5,12	23,933		D ⁽²⁾	
Common	Stock																36	5,701		D ⁽⁴⁾	
		Ta	ble II -									osed of, convertib					wnec	k			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	if any	emed iion Date, i/Day/Year)	4. Trans Code 8)				6. Date Exerc Expiration Da (Month/Day/\)		ate	7. Title and Amount of Securities Underlying Derivative Security (Ins 3 and 4)		f I	Deri Seci	rice of vative urity tr. 5)	9. Numbe derivative Securities Beneficia Owned Following Reported Transacti (Instr. 4)	e S Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Benefic Owners ct (Instr. 4	
					Code	v		(A)	(D)	Date Exercis	sable	Expiration Date	Title	or	ount mber ares						
		f Reporting Person* tures III, L.P.	,																		
1		(First) VENTURES, L AVE, SUITE 140	LC	ddle)																	
(Street)	N	MA	02	215																	
(City)		(State)	(Zi	0)		_															
		f Reporting Person* tures GP III,]																			
(Last)	OOKLINE .	(First) AVE, SUITE 140		ddle)																	
(Street)	N	MA	02	215		_															

201 BROOKL	INE AVE, SUITE	1401	
(Street)	2.64	02217	
BOSTON	MA	02215	
(City)	(State)	(Zip)	
1. Name and Addr	ess of Reporting Per	son*	
(Last)	(First)	(Middle)	
201 BROOKL	INE AVE, SUITE	1401	
(Street)			
BOSTON	MA	02215	
(City)	(State)	(Zip)	

Explanation of Responses:

- 1. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$9.10 to \$9.54, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1).
- 2. These shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual manager of TRV GP III LLC is Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III, LLC, and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.
- 3. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$9.12 to \$9.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3).
- 4. The shares are directly held by Tepper.

Remarks:

/s/ Kevin Gillis, Chief Operating Officer of TRV GP III, LLC, general partner of 01/26/2023 Third Rock Ventures GP III, L.P., general partner of Third Rock Ventures III, L.P. /s/ Kevin Gillis, Chief Operating Officer of TRV GP 01/26/2023 III, LLC, general partner of Third Rock Ventures GP III, <u>L.P</u>. /s/ Kevin Gillis, Chief Operating Officer of TRV GP 01/26/2023 III, LLC /s/ Kevin Gillis, by power of 01/26/2023 attorney for Dr. Robert Tepper ** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.